Healthcare Industry News: Boston Scientific
News Release - February 26, 2009
Gregory J. Tibbitts Appointed Chief Financial Officer at Accumetrics, Inc.SAN DIEGO, Calif., Feb. 26 -- (Healthcare Sales & Marketing Network) -- Accumetrics, Inc. announced today that the Company has appointed Gregory J. Tibbitts, CPA to the position of Chief Financial Officer.
"We believe Greg's extensive experience in both private and public companies will help Accumetrics to advance our financial operations and bring continued success to the Company," says Timothy I. Still, Chief Executive Officer at Accumetrics. "His deep knowledge of the capital markets and the medical device arena will be important as we maximize the commercial opportunity for our technology."
Mr. Tibbitts's background includes 19 years of corporate finance and technical accounting experience balanced between public accounting and private industry. He has held positions with both publicly traded and privately-held companies, with expertise in risk management, treasury, financing and financial operations.
Prior to Accumetrics, Mr. Tibbitts served as Chief Financial Officer of CryoCor, a publicly-traded medical device company, prior to its acquisition by Boston Scientific Corporation. Mr. Tibbitts joined CryoCor in mid-2004, and was heavily involved in both its Initial Public Offering in July 2005 and its ultimate acquisition in 2008 by Boston Scientific. Before joining CryoCor, Mr. Tibbitts served as Chief Financial Officer of Elitra Pharmaceuticals, a privately-held biotechnology company, and as a Senior Manager in the audit practice of Ernst & Young LLP.
Mr. Tibbitts received a BBA degree from the University of San Diego, and an MBA from San Diego State University, and serves on the Board of Directors of IDMI Pharmaceuticals, a publicly-traded biotechnology company.
About Accumetrics (www.accumetrics.com)
Accumetrics is committed to advancing medical understanding of platelet response and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.
Accumetrics' VerifyNow System is the first rapid and easy to use platform for measuring an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, Plavix®, ReoPro®, and Integrilin®, the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions.
The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.